A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected Adults

作者：Scriba Thomas J^*; Tameris Michele; Smit Erica; van der Merwe Linda; Hughes E Jane; Kadira Blessing; Mauff Katya; Moyo Sizulu; Brittain Nathaniel; Lawrie Alison; Mulenga Humphrey; de Kock Marwou; Makhethe Lebohang; van Ren**urg Esme Janse; Gelderbloem Sebastian; Veldsman Ashley; Hatherill Mark; Geldenhuys Hendrik; Hill Adrian V S; Hawkridge Anthony; Hussey Gregory D; Hanekom Willem A; McShane Helen; Mahomed Hassan

来源：American Journal of Respiratory and Critical Care Medicine, 2012, 185(7): 769-778.

DOI：10.1164/rccm.201108-1548OC

• tuberculosis
• HIV-1
• vaccine
• MVA85A
• clinical trial

Rationale: Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. %26lt;br%26gt;Objective To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infected persons in a setting where TB and HIV are endemic. %26lt;br%26gt;Methods: An open-label, phase ha trial was conducted in 48 adults with M.tb and/or HIV infection. Safety and immunogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 x 10(7) plaque-forming units of MVA85A. Specific T-cell responses were characterized by IFN-gamma enzyme-linked immunospot and whole blood intracellular cytokine staining assays. %26lt;br%26gt;Measurements and Main Results: MVA85A was well tolerated and no vaccine-related serious adverse events were recorded. MVA85A induced robust and durable response of mostly polyfunctional CD4(+) T cells, coexpressing IFN-gamma, tumor necrosis factor-alpha, and IL-2. Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infected, compared with HIV-uninfected, vaccinees. No significant effect of antiretroviral therapy on immunogenicity of MVA85A was observed. %26lt;br%26gt;Conclusions: MVA85A was safe and immunogenic in persons with HIV and/or M.tb infection. These results support further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations.

• 出版日期2012-4-1